Zoledronic acid: new preparation. Just a me-too: no advance in hypercalcemia of malignancy.
Pamidronic acid is the standard diphosphonate for the treatment of hypercalcemia of malignancy. Zoledronic acid, a more recent drug, was compared with pamidronic acid in two clinical trials, but the results are unconvincing because of the unusually poor performance of pamidronic acid. Safety of zoledronic acid is uncertain, owing to a lack of long-term data.
D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D005602:France; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology; D009369:Neoplasms / Q000150:complications; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D004164:Diphosphonates